论文部分内容阅读
目的:研究树突状细胞(DC)和细胞因子活化的杀伤细胞(CIK)联合治疗对各种恶性肿瘤术后预防复发和进一步治疗的临床疗效及不良反应,阐明细胞免疫治疗作为肿瘤术后化疗的替代方案的可行性。方法:15例恶性肿瘤术后患者中,13例经CT检查无肿瘤复发,1例肝脏肿瘤转移,1例肝脏有囊肿。患者采用IL-210×105U/d静脉滴入5d。96h后采集患者外周血6～8L,(3～6)×109核细胞。细胞贴壁分离,在含有DC、IL-4、GM-CSF和相应肺癌抗原的无血清培养液培养8d,经静脉注入(32±15.3)×107DC细胞。未贴壁的悬浮细胞加入含有细胞因子培养液培养,诱导生成CIK细胞,皮下注射,1次/周,共注射3次〔(87±35.6)×108CIK细胞〕。周期结束后1个月复查,每隔3个月复查1次。结果:经DC+CIK治疗后,15例中有14例无肿瘤复发或病情加重,其中1例出现肿瘤原位复发并病情加重,但15例患者均存活。临床症状显示,13例患者自感临床症状有明显改善。不良反应观察显示,13例出现1～2次发热,体温37.5～40.2℃。结论:DC+CIK治疗有预防肿瘤复发的疗效,且效率高、不良反应小,是一种有效的肿瘤术后预防性治疗方案。
Objective: To study the clinical efficacy and adverse reactions of dendritic cells (DCs) combined with cytokine-activated killer cells (CIKs) in the prevention and treatment of recurrence and further treatment of various malignancies after operation, and to clarify the effect of cellular immunotherapy as a postoperative chemotherapy The feasibility of alternative solutions. Methods: Of the 15 patients with malignant tumors, 13 had no tumor recurrence after CT examination, 1 had liver metastases, and 1 had cysts in the liver. Patients with IL-210 × 105U / d intravenous infusion of 5d. After 96h, 6 ~ 8L, (3 ~ 6) × 109 nuclear cells were collected from peripheral blood of patients. Cells were detached from the cells and cultured for 8 days in serum-free medium containing DC, IL-4, GM-CSF and corresponding lung cancer antigens. (32 ± 15.3) × 107 DC cells were injected intravenously. Adherent cells were cultured in culture medium containing cytokines to induce the generation of CIK cells. Subcutaneous injection was performed once a week for three times ([87 ± 35.6] × 108CIK cells). 1 month after the end of the cycle of review, review once every 3 months. Results: After the treatment of DC + CIK, 14 of 15 patients had no tumor recurrence or exacerbations. One of the 15 patients had recurrent tumor and exacerbated the disease, but all 15 patients survived. Clinical symptoms showed that 13 patients had significant improvement in their clinical symptoms. Adverse reactions observed, 13 cases of 1 or 2 fever, body temperature 37.5 ~ 40.2 ℃. Conclusion: DC + CIK treatment has the efficacy of preventing tumor recurrence, and has high efficiency and small adverse reaction, which is an effective postoperative preventive treatment for cancer.